{"name":"Coronavirus disease 2019 (COVID-19) in solid organ transplantation: systematic review","id":"53","link":"https://www.clinicsjournal.com/article/covid-19-in-solid-organ-transplantation-patients-a-systematic-review/","dbsearches":"4","refs":"https://docs.google.com/spreadsheets/d/11FSDt7eLkbtsH7DKOHaRHtL3CrCF6wH09J_6kDSIJHg/edit#gid=0","references":[{"doi":"10.5858/arpa.2020-0186-SA","date":"2023-05-11","title":"'COVID-19\u2013Associated Hepatitis Complicating Recent Living Donor Liver Transplantation'","abstract":"'We present a case of COVID-19 hepatitis in a living donor liver allograft recipient whose donor subsequently tested positive for COVID-19. The patient is a female infant with biliary atresia (failed Kasai procedure).\n She recovered well, with improving liver function tests for 4 days.\n On postoperative day 4 the patient developed respiratory distress and fever.\n COVID-19 testing (polymerase chain reaction) was positive.\n Liver function test results increased approximately 5-fold.\n Liver biopsy showed moderate acute hepatitis with prominent clusters of apoptotic hepatocytes and associated cellular debris.\n Lobular lymphohistiocytic inflammation was noted.\n Typical portal features of mild to moderate acute cellular rejection were also noted.\n","id":"10.5858/arpa.2020-0186-SA","idformat":"CROSSREF","foundapis":"","miscinfo":"PUBLISHER: Archives of Pathology and Laboratory Medicine","authors":[{"firstname":"Stephen M.","surname":"Lagana","email":"xref no email","contributions":"1"},{"firstname":" Simona","surname":"De Michele","email":"xref no email","contributions":"1"},{"firstname":" Michael J.","surname":"Lee","email":"xref no email","contributions":"1"},{"firstname":" Jean C.","surname":"Emond","email":"xref no email","contributions":"1"},{"firstname":" Adam D.","surname":"Griesemer","email":"xref no email","contributions":"1"},{"firstname":" Sheryl A.","surname":"Tulin-Silver","email":"xref no email","contributions":"1"},{"firstname":" Elizabeth C.","surname":"Verna","email":"xref no email","contributions":"1"},{"firstname":" Mercedes","surname":"Martinez","email":"xref no email","contributions":"1"},{"firstname":"       Jay H.","surname":"Lefkowitch","email":"xref no email","contributions":"1"}]},{"doi":"10.1111/ajt.15929","date":"2020-04-09","title":"COVID-19 in solid organ transplant recipients: A single-center case series from Spain","abstract":"The clinical characteristics, management, and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplant (SOT) remain unknown.\n\n We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%], and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid.\n\n Median age at diagnosis was 71.0 ± 12.8 years, and the median interval since transplantation was 9.3 years.\n\n Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations.\n\n Lopinavir/ritonavir (usually associated with hydroxychloroquine) was used in 50.0% of patients and had to be prematurely discontinued in 2 of them.\n\n Other antiviral regimens included hydroxychloroquine monotherapy (27.8%) and interferon-? (16.7%).\n\n As of April 4, the case-fatality rate was 27.8% (5/18).\n\n After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home.\n\n C-reactive protein levels at various points were significantly higher among recipients who experienced unfavorable outcome.\n\n In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients.\n\n","id":"PMC9800471","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Mario","surname":"Fernández-Ruiz","email":"NULL","contributions":"2"},{"firstname":" Amado","surname":"Andrés","email":"NULL","contributions":"2"},{"firstname":" Carmelo","surname":"Loinaz","email":"NULL","contributions":"2"},{"firstname":" Juan F.","surname":"Delgado","email":"NULL","contributions":"2"},{"firstname":" Francisco","surname":"López-Medrano","email":"NULL","contributions":"2"},{"firstname":" Rafael","surname":"San Juan","email":"NULL","contributions":"2"},{"firstname":" Esther","surname":"González","email":"NULL","contributions":"2"},{"firstname":" Natalia","surname":"Polanco","email":"NULL","contributions":"2"},{"firstname":" María D.","surname":"Folgueira","email":"NULL","contributions":"2"},{"firstname":" Antonio","surname":"Lalueza","email":"NULL","contributions":"2"},{"firstname":" Carlos","surname":"Lumbreras","email":"NULL","contributions":"2"},{"firstname":"                           José M.","surname":"Aguado","email":"NULL","contributions":"2"}]},{"doi":"10.1111/ajt.15919","date":"1970-01-01","title":"First case of COVID-19 in a kidney transplant recipient treated with belatacept","abstract":"","id":"PMC7262359","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"David","surname":"Marx","email":"NULL","contributions":"1"},{"firstname":" Bruno","surname":"Moulin","email":"NULL","contributions":"1"},{"firstname":" Samira","surname":"Fafi-Kremer","email":"NULL","contributions":"2"},{"firstname":" Ilies","surname":"Benotmane","email":"NULL","contributions":"1"},{"firstname":" Gabriela","surname":"Gautier","email":"NULL","contributions":"1"},{"firstname":" Peggy","surname":"Perrin","email":"NULL","contributions":"1"},{"firstname":"                           Sophie","surname":"Caillard","email":"NULL","contributions":"1"}]},{"doi":"10.1111/tid.13286","date":"2020-03-31","title":"Threatening drug?drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID?19)","abstract":"During the novel coronavirus pandemic, organ transplant recipients represent a frail susceptible category due to long?term immunosuppressive therapy.\n\n For this reason, clinical manifestations may differ from general population and different treatment approaches may be needed.\n\n We present the case of a 36?year?old kidney?transplanted woman affected by Senior?Loken syndrome diagnosed with COVID?19 pneumonia after a contact with her positive mother.\n\n Initial symptoms were fatigue, dry cough, and coryza; she never had fever nor oxygen supplementation.\n\n Hydroxychloroquine and lopinavir/ritonavir were started, and the antiviral drug was replaced with darunavir/cobicistat after 2 days for diarrhea.\n\n Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction.\n\n The patient was left with steroid therapy alone.\n\n The peculiarity of clinical presentation and the management difficulties represent the flagship of our case report.\n\n We stress the need for guidelines in transplant recipients with COVID?19 infection with particular regard to the management of therapy.\n\n","id":"PMC7262190","idformat":"PMC","foundapis":"_PMC_CROSSREF","miscinfo":"","authors":[{"firstname":"Marilù","surname":"Bartiromo","email":"bartiromom@aou-careggi.toscana.it","contributions":"1"},{"firstname":" Beatrice","surname":"Borchi","email":"NULL","contributions":"1"},{"firstname":" Annarita","surname":"Botta","email":"NULL","contributions":"2"},{"firstname":" Annarita","surname":"Botta","email":"NULL","contributions":"0"},{"firstname":" Alfredo","surname":"Bagalà","email":"NULL","contributions":"2"},{"firstname":" Alfredo","surname":"Bagalà","email":"NULL","contributions":"0"},{"firstname":" Gianmarco","surname":"Lugli","email":"NULL","contributions":"1"},{"firstname":" Marta","surname":"Tilli","email":"NULL","contributions":"2"},{"firstname":" Marta","surname":"Tilli","email":"NULL","contributions":"0"},{"firstname":" Annalisa","surname":"Cavallo","email":"NULL","contributions":"1"},{"firstname":" Brunilda","surname":"Xhaferi","email":"NULL","contributions":"1"},{"firstname":" Roberta","surname":"Cutruzzulà","email":"NULL","contributions":"1"},{"firstname":" Augusto","surname":"Vaglio","email":"NULL","contributions":"1"},{"firstname":" Silvia","surname":"Bresci","email":"NULL","contributions":"1"},{"firstname":" Aida","surname":"Larti","email":"NULL","contributions":"1"},{"firstname":" Alessandro","surname":"Bartoloni","email":"NULL","contributions":"1"},{"firstname":"                           Calogero","surname":"Cirami","email":"NULL","contributions":"1"}]},{"doi":"10.1111/ajt.15897","date":"2020-03-20","title":"Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report","abstract":"An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in Wuhan, China, with cases now confirmed in multiple countries.\n\n The clinical course of patients remains to be fully characterized, clinical presentation ranges from asymptomatic infection to acute respiratory distress syndrome and acute renal failure, and no pharmacological therapies of proven efficacy yet exist.\n\n We report a case of SARS-CoV-2 infection in a renal transplant recipient with excellent outcome.\n\n This case states the importance of close monitoring of the concentration of cyclosporine in patients treated with lopinavir/ritonavir; the routine treatment of corticosteroid can be continued.\n\n This is a rare report of SARS-CoV-2 infection in a renal transplant recipient.\n\n Further data are needed to achieve better understanding of the impact of immunosuppressive therapy on the clinical presentation, severity, and outcome of SARS-CoV-2 infections in solid organ transplant recipients.\n\n","id":"PMC7262121","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Ling","surname":"Ning","email":"NULL","contributions":"1"},{"firstname":" Lei","surname":"Liu","email":"NULL","contributions":"0"},{"firstname":" Wenyuan","surname":"Li","email":"NULL","contributions":"1"},{"firstname":" Hongtao","surname":"Liu","email":"NULL","contributions":"1"},{"firstname":" Jizhou","surname":"Wang","email":"NULL","contributions":"1"},{"firstname":" Ziqin","surname":"Yao","email":"NULL","contributions":"1"},{"firstname":" Shengyu","surname":"Zhang","email":"NULL","contributions":"1"},{"firstname":" Desheng","surname":"Zhao","email":"NULL","contributions":"1"},{"firstname":" Björn","surname":"Nashan","email":"NULL","contributions":"1"},{"firstname":" Aizong","surname":"Shen","email":"NULL","contributions":"1"},{"firstname":" Lianxin","surname":"Liu","email":"NULL","contributions":"2"},{"firstname":"                           Lei","surname":"Li","email":"NULL","contributions":"3"}]},{"doi":"10.1016/j.eururo.2020.03.036","date":"1970-01-01","title":"COVID-19 in a Kidney Transplant Patient","abstract":"","id":"PMC7271211","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Junpeng","surname":"Wang","email":"NULL","contributions":"1"},{"firstname":" Xin","surname":"Li","email":"NULL","contributions":"3"},{"firstname":" Guanghui","surname":"Cao","email":"NULL","contributions":"1"},{"firstname":" Xiaoqiang","surname":"Wu","email":"NULL","contributions":"1"},{"firstname":" Zhiwei","surname":"Wang","email":"NULL","contributions":"1"},{"firstname":"                           Tianzhong","surname":"Yan","email":"ytz460@hotmail.com","contributions":"1"}]},{"doi":"10.1016/j.eururo.2020.03.030","date":"2020-03-20","title":"Identification of Kidney Transplant Recipients with Coronavirus Disease 2019","abstract":"Coronavirus disease 2019 (COVID-19) is a novel and lethal infectious disease, posing a threat to global health security.\n\n The number of cases has increased rapidly, but no data concerning kidney transplant (KTx) recipients infected with COVID-19 are available.\n\n To present the epidemiological, clinical, and therapeutic characteristics of KTx recipients infected with COVID-19, we report on a case series of five patients who were confirmed as having COVID-19 through nucleic acid testing (NAT) from January 1, 2020 to February 28, 2020. The most common symptoms on admission to hospital were fever (five patients, 100%), cough (five patients, 100%), myalgia or fatigue (three patients, 60%), and sputum production (three patients, 60%); serum creatinine or urea nitrogen levels were slightly higher than those before symptom onset.\n\n Four patients received a reduced dose of maintenance immunosuppressive therapy during hospitalization.\n\n As of March 4, 2020 NAT was negative for COVID-19 in three patients twice in succession, and their computed tomography scans showed improved images.\n\n Although greater patient numbers and long-term follow-up data are needed, our series demonstrates that mild COVID-19 infection in KTx recipients can be managed using symptomatic support therapy combined with adjusted maintenance immunosuppressive therapy.\n\n","id":"PMC7270372","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Hui","surname":"Zhang","email":"NULL","contributions":"1"},{"firstname":" Yan","surname":"Chen","email":"NULL","contributions":"1"},{"firstname":" Quan","surname":"Yuan","email":"NULL","contributions":"1"},{"firstname":" Qiu-Xiang","surname":"Xia","email":"NULL","contributions":"1"},{"firstname":" Xian-Peng","surname":"Zeng","email":"NULL","contributions":"1"},{"firstname":" Jing-Tao","surname":"Peng","email":"NULL","contributions":"1"},{"firstname":" Jing","surname":"Liu","email":"NULL","contributions":"3"},{"firstname":" Xing-Yuan","surname":"Xiao","email":"NULL","contributions":"1"},{"firstname":" Guo-Song","surname":"Jiang","email":"NULL","contributions":"1"},{"firstname":" Han-Yu","surname":"Xiao","email":"NULL","contributions":"1"},{"firstname":" Liang-Bo","surname":"Xie","email":"NULL","contributions":"1"},{"firstname":" Jing","surname":"Chen","email":"NULL","contributions":"2"},{"firstname":" Jia-Li","surname":"Liu","email":"NULL","contributions":"1"},{"firstname":" Xiong","surname":"Xiao","email":"NULL","contributions":"1"},{"firstname":" Hua","surname":"Su","email":"NULL","contributions":"1"},{"firstname":" Chun","surname":"Zhang","email":"NULL","contributions":"1"},{"firstname":" Xiao-Ping","surname":"Zhang","email":"NULL","contributions":"1"},{"firstname":" Hua","surname":"Yang","email":"NULL","contributions":"1"},{"firstname":" Heng","surname":"Li","email":"NULL","contributions":"1"},{"firstname":"                           Zhen-Di","surname":"Wang","email":"wangzhendi@gmail.com","contributions":"1"}]},{"doi":"10.1111/ajt.15903","date":"2020-03-30","title":"A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China","abstract":"In December 2019, an outbreak of COVID-19 occurred in Wuhan, China, and spread to the whole of China and to multiple countries worldwide.\n\n Unlike SARS and MERS, where secondary transmission mostly occurred in hospital settings, COVID-19 transmission occurs in large numbers within families.\n\n Herein we report three cases of a familial cluster with one family member being a kidney transplant recipient.\n\n The initial clinical symptoms of COVID-19 in these three patients were the same, but their progression was different.\n\n Based on the severity of clinical symptoms, chest computer tomography findings and SARS-Cov-2 RNA test results, we admitted the husband to the respiratory intensive care unit (RICU) and used a treatment consisting of immunosuppressant reduction/cessation and low dose methylprednisolone-based therapy, and his wife to the respiratory isolation ward.\n\n In contrast, the son received in-home isolation and home-based care.\n\n All three family members made a full recovery.\n\n","id":"PMC9800498","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Song","surname":"Chen","email":"NULL","contributions":"1"},{"firstname":" Qin","surname":"Yin","email":"NULL","contributions":"1"},{"firstname":" Huibo","surname":"Shi","email":"NULL","contributions":"2"},{"firstname":" Dunfeng","surname":"Du","email":"NULL","contributions":"1"},{"firstname":" Sheng","surname":"Chang","email":"NULL","contributions":"1"},{"firstname":" Li","surname":"Ni","email":"NULL","contributions":"1"},{"firstname":" Haifang","surname":"Qiu","email":"NULL","contributions":"1"},{"firstname":" Zhishui","surname":"Chen","email":"NULL","contributions":"2"},{"firstname":" Jixian","surname":"Zhang","email":"NULL","contributions":"1"},{"firstname":"                           Weijie","surname":"Zhang","email":"NULL","contributions":"1"}]},{"doi":"10.1111/ajt.15902","date":"2020-03-27","title":"SARS Cov-2 infection in a renal-transplanted patient: A case report","abstract":"The clinical manifestation of COVID-19 can vary from an asymptomatic course to ARDS requiring invasive mechanical ventilation and extracorporeal membrane oxygenation.\n\n A kidney transplanted patient infected with SARS CoV-2 infection showed a mild disease despite immune suppression.\n\n It is possible that Immunosuppression can “be protective” as the cytokine storm is an important factor in the disease story.\n\n Despite the good outcome reported in the present case report, is remains of vital importance the solid organ transplant patients use precautions in order to avoid the infection.\n\n","id":"PMC9800469","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Elena","surname":"Seminari","email":"NULL","contributions":"1"},{"firstname":" Marta","surname":"Colaneri","email":"NULL","contributions":"1"},{"firstname":" Margherita","surname":"Sambo","email":"NULL","contributions":"1"},{"firstname":" Ilaria","surname":"Gallazzi","email":"NULL","contributions":"1"},{"firstname":" Angela","surname":"Di Matteo","email":"NULL","contributions":"1"},{"firstname":" Silvia","surname":"Roda","email":"NULL","contributions":"1"},{"firstname":" Raffaele","surname":"Bruno","email":"NULL","contributions":"0"},{"firstname":"                           NULL","surname":"NULL","email":"NULL","contributions":"0"}]},{"doi":"10.1111/ajt.15891","date":"1970-01-01","title":"COVID-19 in kidney transplant recipients","abstract":"","id":"PMC7228396","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Ilaria","surname":"Gandolfini","email":"NULL","contributions":"1"},{"firstname":" Marco","surname":"Delsante","email":"NULL","contributions":"1"},{"firstname":" Enrico","surname":"Fiaccadori","email":"NULL","contributions":"1"},{"firstname":" Gianluigi","surname":"Zaza","email":"NULL","contributions":"1"},{"firstname":" Lucio","surname":"Manenti","email":"NULL","contributions":"1"},{"firstname":" Anna","surname":"Degli Antoni","email":"NULL","contributions":"1"},{"firstname":" Licia","surname":"Peruzzi","email":"NULL","contributions":"1"},{"firstname":" Leonardo V.","surname":"Riella","email":"NULL","contributions":"1"},{"firstname":" Paolo","surname":"Cravedi","email":"NULL","contributions":"1"},{"firstname":"                           Umberto","surname":"Maggiore","email":"NULL","contributions":"1"}]},{"doi":"10.1111/ajt.15874","date":"2020-03-17","title":"Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?","abstract":"COVID-19 is novel infectious disease with an evolving understanding of its epidemiology and clinical manifestations.\n\n Immunocompromised patients often present atypical presentations of viral diseases.\n\n Herein we report a case of a COVID-19 infection in a solid organ transplant recipient, in which the first clinical symptoms were of gastrointestinal viral disease and fever, which further progressed to respiratory symptoms in 48 hours.\n\n In these high risk populations, protocols for screening for SARS-Cov2 may be needed to be re-evaluated.\n\n","id":"PMC7228209","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Elena","surname":"Guillen","email":"NULL","contributions":"1"},{"firstname":" Gaston J.","surname":"Pineiro","email":"NULL","contributions":"1"},{"firstname":" Ignacio","surname":"Revuelta","email":"NULL","contributions":"1"},{"firstname":" Diana","surname":"Rodriguez","email":"NULL","contributions":"1"},{"firstname":" Marta","surname":"Bodro","email":"NULL","contributions":"1"},{"firstname":" Asunción","surname":"Moreno","email":"NULL","contributions":"1"},{"firstname":" Josep M.","surname":"Campistol","email":"NULL","contributions":"1"},{"firstname":" Fritz","surname":"Diekmann","email":"NULL","contributions":"1"},{"firstname":"                           Pedro","surname":"Ventura-Aguiar","email":"NULL","contributions":"1"}]},{"doi":"10.1111/ajt.15929","date":"2020-04-09","title":"COVID-19 in solid organ transplant recipients: A single-center case series from Spain","abstract":"The clinical characteristics, management, and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplant (SOT) remain unknown.\n\n We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%], and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid.\n\n Median age at diagnosis was 71.0 ± 12.8 years, and the median interval since transplantation was 9.3 years.\n\n Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations.\n\n Lopinavir/ritonavir (usually associated with hydroxychloroquine) was used in 50.0% of patients and had to be prematurely discontinued in 2 of them.\n\n Other antiviral regimens included hydroxychloroquine monotherapy (27.8%) and interferon-? (16.7%).\n\n As of April 4, the case-fatality rate was 27.8% (5/18).\n\n After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home.\n\n C-reactive protein levels at various points were significantly higher among recipients who experienced unfavorable outcome.\n\n In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients.\n\n","id":"PMC9800471","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Mario","surname":"Fernández-Ruiz","email":"NULL","contributions":"0"},{"firstname":" Amado","surname":"Andrés","email":"NULL","contributions":"0"},{"firstname":" Carmelo","surname":"Loinaz","email":"NULL","contributions":"0"},{"firstname":" Juan F.","surname":"Delgado","email":"NULL","contributions":"0"},{"firstname":" Francisco","surname":"López-Medrano","email":"NULL","contributions":"0"},{"firstname":" Rafael","surname":"San Juan","email":"NULL","contributions":"0"},{"firstname":" Esther","surname":"González","email":"NULL","contributions":"0"},{"firstname":" Natalia","surname":"Polanco","email":"NULL","contributions":"0"},{"firstname":" María D.","surname":"Folgueira","email":"NULL","contributions":"0"},{"firstname":" Antonio","surname":"Lalueza","email":"NULL","contributions":"0"},{"firstname":" Carlos","surname":"Lumbreras","email":"NULL","contributions":"0"},{"firstname":"                           José M.","surname":"Aguado","email":"NULL","contributions":"0"}]},{"doi":"10.1111/ajt.15928","date":"2020-04-07","title":"Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients","abstract":"Over 1 000 000 cases of coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide outbreak began.\n\n Not enough data on infected solid organ transplant (SOT) recipients are available, especially data about the management of immunosuppressants.\n\n We report two cases of COVID-19 in two transplant recipients, with different treatments and prognoses.\n\n The first patient received liver transplantation due to hepatitis B virus–related hepatocellular carcinoma and was confirmed to have COVID-19 9 days later.\n\n Following a treatment regimen consisting of discontinued immunosuppressant use and low-dose methylprednisolone-based therapy, the patient developed acute rejection but eventually recovered.\n\n The other patient had undergone a renal transplant from a living-related donor 17 years ago, and was admitted to the hospital because of persistent fever.\n\n This patient was also diagnosed with COVID-19. His treatment regimen consisted of reduced immunosuppressant use.\n\n No signs of rejection were observed during the regimen.\n\n In the end, the patient successfully recovered from COVID-19. These effectively treated cases can provide a basis for immunosuppressant management of COVID-19-positive SOT recipients.\n\n","id":"PMC7262295","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Zibiao","surname":"Zhong","email":"NULL","contributions":"1"},{"firstname":" Qiuyan","surname":"Zhang","email":"NULL","contributions":"1"},{"firstname":" Haoyang","surname":"Xia","email":"NULL","contributions":"1"},{"firstname":" Aiping","surname":"Wang","email":"NULL","contributions":"1"},{"firstname":" Wenjin","surname":"Liang","email":"NULL","contributions":"1"},{"firstname":" Wei","surname":"Zhou","email":"NULL","contributions":"1"},{"firstname":" Lihua","surname":"Zhou","email":"NULL","contributions":"1"},{"firstname":" Xiao","surname":"Liu","email":"NULL","contributions":"1"},{"firstname":" Lingzhang","surname":"Rao","email":"NULL","contributions":"1"},{"firstname":" Zhifeng","surname":"Li","email":"NULL","contributions":"1"},{"firstname":" Zhiyong","surname":"Peng","email":"NULL","contributions":"1"},{"firstname":" Pingzheng","surname":"Mo","email":"NULL","contributions":"0"},{"firstname":" Yong","surname":"Xiong","email":"NULL","contributions":"0"},{"firstname":" Shaojun","surname":"Ye","email":"NULL","contributions":"1"},{"firstname":" Yanfeng","surname":"Wang","email":"NULL","contributions":"1"},{"firstname":"                           Qifa","surname":"Ye","email":"NULL","contributions":"1"}]},{"doi":"10.1002/hep.31257","date":"2023-04-24","title":"'Perioperative Presentation of COVID\u201019 Disease in a Liver Transplant Recipient'","abstract":"Unknown Abstract","id":"10.1002/hep.31257","idformat":"CROSSREF","foundapis":"","miscinfo":"PUBLISHER: Ovid Technologies (Wolters Kluwer Health)","authors":[{"firstname":"Juanjuan","surname":"Qin","email":"xref no email","contributions":"1"},{"firstname":" Haitao","surname":"Wang","email":"xref no email","contributions":"1"},{"firstname":" Xian","surname":"Qin","email":"xref no email","contributions":"1"},{"firstname":" Peng","surname":"Zhang","email":"xref no email","contributions":"1"},{"firstname":" Lihua","surname":"Zhu","email":"xref no email","contributions":"1"},{"firstname":" Jingjing","surname":"Cai","email":"xref no email","contributions":"1"},{"firstname":" Yufeng","surname":"Yuan","email":"xref no email","contributions":"1"},{"firstname":"       Hongliang","surname":"Li","email":"xref no email","contributions":"1"}]},{"doi":"10.1111/ajt.15909","date":"2020-04-06","title":"Fatal outcome in a liver transplant recipient with COVID-19","abstract":"Liver injury is common in patients with COVID-19, but little is known about its clinical presentation and severity in the context of liver transplant.\n\n We describe a case of COVID-19 in a patient who underwent transplant 3 years ago for hepatocellular carcinoma.\n\n The patient came to clinic with symptoms of respiratory disease; pharyngeal swabs for severe acute respiratory syndrome coronavirus 2 were positive.\n\n His disease progressed rapidly from mild to critical illness and was complicated by several nosocomial infections and multiorgan failure.\n\n Despite multiple invasive procedures and rescue therapies, he died from the disease.\n\n The management of COVID-19 in the posttransplant setting presents complex challenges, emphasizing the importance of strict prevention strategies.\n\n","id":"PMC7262021","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Jiao-Feng","surname":"Huang","email":"NULL","contributions":"1"},{"firstname":" Kenneth I.","surname":"Zheng","email":"NULL","contributions":"1"},{"firstname":" Jacob","surname":"George","email":"NULL","contributions":"1"},{"firstname":" Hai-Nv","surname":"Gao","email":"NULL","contributions":"1"},{"firstname":" Ru-Nan","surname":"Wei","email":"NULL","contributions":"1"},{"firstname":" Hua-Dong","surname":"Yan","email":"NULL","contributions":"1"},{"firstname":"                           Ming-Hua","surname":"Zheng","email":"NULL","contributions":"2"}]},{"doi":"10.1111/ajt.15901","date":"2020-04-01","title":"Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient","abstract":"Coronavirus disease 2019 (COVID-19) pandemic spreads rapidly and may be an increasing challenge for transplant community.\n\n Clinical data on COVID-19 infection in transplant population is very limited.\n\n Herein we presented the clinical course and outcome of a 50-year-old male post liver transplantation who contracted COVID-19, with subsequent infection of his wife.\n\n The process of illness was representative.\n\n A therapeutic regime with temporary immunosuppression withdrawal and systemic low-dose corticosteroid as principle was involved in the management of the patient which made him recover from severe COVID-19 pneumonia.\n\n","id":"PMC9800465","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Bin","surname":"Liu","email":"NULL","contributions":"1"},{"firstname":" Yangzhong","surname":"Wang","email":"NULL","contributions":"1"},{"firstname":" Yuanyuan","surname":"Zhao","email":"NULL","contributions":"1"},{"firstname":" Huibo","surname":"Shi","email":"NULL","contributions":"0"},{"firstname":" Fanjun","surname":"Zeng","email":"NULL","contributions":"1"},{"firstname":"                           Zhishui","surname":"Chen","email":"NULL","contributions":"0"}]},{"doi":"10.1016/S2468-1253(20)30116-3","date":"1970-01-01","title":"COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy","abstract":"","id":"PMC7146678","idformat":"PMC","foundapis":"_PMC_elsevier_CROSSREF","miscinfo":"","authors":[{"firstname":"Sherrie","surname":"Bhoori","email":"NULL","contributions":"1"},{"firstname":" Roberta Elisa","surname":"Rossi","email":"NULL","contributions":"1"},{"firstname":" Davide","surname":"Citterio","email":"NULL","contributions":"1"},{"firstname":"                           Vincenzo","surname":"Mazzaferro","email":"NULL","contributions":"1"}]},{"doi":"10.1002/lt.25756","date":"1970-01-01","title":"Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic","abstract":"Unknown Abstract","id":"10.1002/lt.25756","idformat":"CORE","foundapis":"_CROSSREF","miscinfo":"","authors":[{"firstname":"Severe","surname":"Acute Respiratory Syndrome (","email":"coreGivesNoEmail","contributions":"1"}]}]}